<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205488</url>
  </required_header>
  <id_info>
    <org_study_id>NILO-PD</org_study_id>
    <nct_id>NCT03205488</nct_id>
  </id_info>
  <brief_title>Nilotinib in Parkinson's Disease</brief_title>
  <acronym>NILO-PD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of daily oral administration of nilotinib
      (150-300mg once daily) in Parkinson's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if nilotinib is safe, if it can be tolerated by
      patients with Parkinson's disease (PD) and to learn if nilotinib has the possibility of
      effectively treating PD symptoms. Nilotinib has been approved by the Food and Drug
      Administration (FDA) to treat certain types of cancer (leukemia) but is considered
      investigational in this study because it has not been approved for treating PD. Twenty-five
      sites will enroll participants into 2 cohorts,approximately 75 in Cohort 1 and 60 in Cohort
      2. Participants with moderate to advanced PD symptoms will be enrolled in Cohort 1, randomly
      assigned to take nilotinib (150 mg or 300mg) or placebo, and will complete 13 in-person study
      visits over 8.5 months.

      The results from Cohort 1 will determine if either dose of nilotinib (150mg or 300 mg) is
      safe and tolerable enough to move forward and evaluate in Cohort 2. If either dose is found
      to be safe and tolerable, participants with early PD will be enrolled into Cohort 2.

      Participants in Cohort 2 will be randomly assigned to either nilotinib (dose to be determined
      from Cohort 1 results) or placebo and will complete 17 in-person visits over 14.5 months. For
      both cohorts, the study visits will include clinical assessment of motor, neuropsychiatric
      and cognitive testing as well as collection of blood and cerebral spinal fluid, collected by
      lumbar puncture.

      This study will also evaluate if nilotinib can help improve motor symptoms associated with
      PD. All participants in Cohort 1 and participants in Cohort 2 who have started PD medications
      will have an assessment of the motor exam (Part III) in a practically defined OFF state (12
      hours post dose) and ON state (at least one-hour post dose).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Actual">September 28, 2019</completion_date>
  <primary_completion_date type="Actual">August 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of Nilotinib Over Placebo</measure>
    <time_frame>6 months</time_frame>
    <description>The count of study participants who completed the 6-month study treatment period while active on their original assigned dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Nilotinib</measure>
    <time_frame>We assessed adverse events that were collected from the first dose of study drug until 60 days after the participant's last dose.</time_frame>
    <description>The count of study participants who experienced any treatment-related SAE in each treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in MDS-UPDRS Part III</measure>
    <time_frame>The MDS-UPDRS Part III ON state was collected at baseline, day 14, day 30, month 3, month 6, 30 and 60 days post treatment. The OFF state was collected at baseline, month 3, month 6, 30 and 60 days post treatment.</time_frame>
    <description>The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III is a motor examination in both practically defined medications OFF state (12 hrs post dose) and ON state (based on the participant/site investigator defined best ON and/or approximately 1 hour post dose). Measure Description: The part III subscale score ranges from 0-165. The Larger the value stands for more disability from PD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate to Advanced PD Population Randomized 1:1:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early/de novo Randomized 2:1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)</intervention_name>
    <description>2 capsules taken once daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)</intervention_name>
    <description>2 capsules taken once daily</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules taken once daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria; Cohort 1 and 2:

          1. Idiopathic PD based on the UK Brain Bank diagnostic criteria.

          2. Any race and either gender, age 40-79

          3. Able to read and understand English with the capacity to provide voluntary informed
             consent by signing the informed consent form (ICF)

          4. Willing to comply with all study procedures including multiple lumbar punctures (LP)

          5. Must be on a stable regimen of central nervous system acting medications (if
             applicable) for at least 30 days prior to the baseline visit (e.g., benzodiazepines,
             antidepressants, hypnotics)

        Inclusion criteria specific for Cohort 1:

        6a. Diagnosis of PD duration &gt; 5 year 7a. Hoehn &amp; Yahr scale (H&amp;Y) stage &gt; 2 and &lt; 4 in the
        ON state 8a. Must be on a stable regimen of PD medications, that includes levodopa, for at
        least 30 days prior to the screening visit

        a. Treatment with monoamine oxidase B (MAO-B) inhibitors will be allowed provided the dose
        has been stable for 60 days prior to baseline

        Inclusion criteria specific for Cohort 2:

        6b. Diagnosis of PD duration &lt; 3 years 7b. H&amp;Y stage ≤ 2 8b. Participants who are currently
        NOT receiving symptomatic therapy (ST) (levodopa,dopamine agonists and monoamine oxidase B
        (MAO-B) inhibitors) and NOT projected to require ST for at least 3 months from enrollment.

        a. Treatment with amantadine or an anticholinergic agent will be allowed provided the dose
        has been stable for 30 days prior to screening and will remain stable for the duration of
        the study

        Exclusion Criteria; Cohorts 1 and 2:

          1. Diagnosis of atypical parkinsonism

          2. History of bipolar disorder or major depression, or presence of active depression
             defined as a Beck Depression Inventory II (BDI-II) score &gt;17

          3. History of a suicide attempt within the last 5 years or active suicidal ideations

          4. History of schizophrenia or schizophrenia spectrum disorders

          5. History of uncontrolled hypokalemia or hypomagnesaemia, or laboratory evidence of such
             on screening

          6. History of cardiac arrhythmia, long QT syndrome, or a corrected QT interval (QTcF)
             ≥450ms at screening visit 1

          7. Treated within 30 days prior to randomization, or planned use during the trial with
             any of the following classes of Concomitant drugs:

               1. Class IA or III antiarrhythmic drugs

               2. QT prolonging drugs

               3. Strong CYP3A4 inhibitors or inducers

               4. Anticoagulants

               5. Proton pump inhibitors

          8. A clinical history, or the active presence of a cardiovascular condition including:

               1. Myocardial infarction, known cardiac ischemia, or angina

               2. Cerebrovascular event (e.g. embolic stroke)

               3. Congestive heart failure, symptomatic first degree atrioventricular (AV) block or
                  PR interval &gt; 220msec and all second and third degree AV block, second- or
                  third-degree atrioventricular block, sick sinus syndrome, or other serious
                  cardiac rhythm disturbances

               4. History of Torsade de Pointes

               5. Other cardiovascular history that, in the opinion of the Site Investigator, will
                  preclude study participation

          9. History of hepatic disease, including abnormal liver function defined as Total
             Bilirubin &gt; 1.5 times upper limit, Aspartate Aminotransferase (AST) and/or Alanine
             Aminotransferase (ALT) &gt; 2 times the upper limit of the normal, or coagulopathy with
             INR &gt; 1.4

         10. History of epilepsy or a seizure within the last 6 months

         11. Active malignancy, or history of a neoplasm in the prior 5 years (excluding
             basal/squamous cell carcinoma)

         12. Prior history of pancreatitis or total gastrectomy or evidence of abnormal pancreatic
             function defined as elevated amylase and/or lipase &gt; 2 times upper limit of normal

         13. Diagnosis of human immunodeficiency virus (HIV), clinically significant chronic
             hepatitis such as hepatitis B (HBV) or hepatitis C (HCV), or clinical history or signs
             of an active infection

         14. History of drug or alcohol abuse ≤ 5 years

         15. Active medical or psychiatric condition that in the opinion of the Site Investigator
             should preclude study participation

         16. Previous surgical management for PD

         17. Participants participating in any drug or device clinical investigation concurrently
             or within 30 days prior to screening for this study

         18. Severe lactose and galactose intolerance

         19. Participants with evidence of other significant laboratory abnormalities which in the
             opinion of the site investigator or clinical monitor should preclude study
             participation

         20. Known hypersensitivity or contraindication to study drugs (nilotinib or matching
             placebo) or their components.

         21. Female participants of child-bearing potential. Female participants must be
             post-menopausal, post-hysterectomy, or have a documented infertility based on a known
             medical or surgical condition

         22. Participants with a history of bone marrow suppression or evidence of persistent
             myelosuppression defined as absolute neutrophil count &lt;1.8 X 109/L, significant
             anemia, or thrombocytopenia defined as platelet count &lt; 100 X 109/L

        Exclusion criteria specific for Cohort 1:

        22a. Diagnosis of dementia based on the clinician's assessment, or a Montreal Cognitive
        Assessment (MoCA) score &lt; 21 at baseline

        Exclusion criteria specific for Cohort 2:

        22b.MoCA score &lt; 26 at baseline 23b. Treated within 60 days prior to randomization or
        expected to require treatment within 3 months from randomization with any ST (including
        levodopa and dopamine agonists )

        a. Treatment with amantadine or an anticholinergic agent will be allowed provided the dose
        has been stable for 30 days prior to screening and will remain stable for the duration of
        the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Simuni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado at Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>May 28, 2020</results_first_submitted>
  <results_first_submitted_qc>May 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2020</results_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Tanya Simuni</investigator_full_name>
    <investigator_title>Director, Parkinson's disease and Movement Disorders Center Northwestern University Feinberg School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Northwestern</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>USA</keyword>
  <keyword>NILO-PD</keyword>
  <keyword>Parkinson Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03205488/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03205488/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From November 2017 to December 2018, 125 patients were assessed for eligibility. Of those screened, 76 participants were enrolled in the trial.</recruitment_details>
      <pre_assignment_details>Of the patients assessed for eligibility, 49 (39%) were excluded. 42 patients did not meet inclusion criteria and 7 declined study participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo enclosed in capsules to maintain the blind was administered orally once per day over the course of 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Nilotinib 150</title>
          <description>Patients were administered 1 capsule of 150 mg Nilotinib and 1 capsule of matching placebo each day over the course of 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Nilotinib 300</title>
          <description>Patients were administered 2 capsules of 150 mg Nilotinib each day over the course of 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo enclosed in capsules to maintain the blind was administered orally once per day over the course of 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Nilotinib 150</title>
          <description>Patients were administered 1 capsule of 150 mg Nilotinib and 1 capsule of matching placebo each day over the course of 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Nilotinib 300</title>
          <description>Patients were administered 2 capsules of 150 mg Nilotinib each day over the course of 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="6.8"/>
                    <measurement group_id="B2" value="61.2" spread="7.4"/>
                    <measurement group_id="B3" value="66.9" spread="7.3"/>
                    <measurement group_id="B4" value="64.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parkinson’s Disease History</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Parkinson’s Disease Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.4" spread="4.9"/>
                    <measurement group_id="B2" value="8.5" spread="3.2"/>
                    <measurement group_id="B3" value="11.7" spread="5.2"/>
                    <measurement group_id="B4" value="9.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at Diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="6.8"/>
                    <measurement group_id="B2" value="52.7" spread="7.6"/>
                    <measurement group_id="B3" value="55.2" spread="9.3"/>
                    <measurement group_id="B4" value="54.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDS-UPDRS Total Score</title>
          <description>Measure Description: Baseline total Unified Parkinson Disease Rating Scale (UPDRS) score ranges from 0 to 295. The higher the value the more disability from PD the participant has.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>MDS-UPDRS Total OFF Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="21.3"/>
                    <measurement group_id="B2" value="65.0" spread="16.0"/>
                    <measurement group_id="B3" value="70.2" spread="20.2"/>
                    <measurement group_id="B4" value="66.4" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDS-UPDRS Total ON Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="17.8"/>
                    <measurement group_id="B2" value="46.9" spread="15.1"/>
                    <measurement group_id="B3" value="51.9" spread="15.7"/>
                    <measurement group_id="B4" value="48.4" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parkinson’s Disease Classifications</title>
          <description>Measure Description: Hoehn and Yahr staging of severity of Parkinson's disease. Baseline H/Y stage ranges from &gt;2 to &lt;4. Larger value stands for more disability from PD. H&amp;Y 2 = Bilateral involvement without impairment of balance. H&amp;Y 3 = Mild to moderate involvement; some postural instability but physically independent; needs assistance to recover from pull test. 4 = Severe disability; still able to walk or stand unassisted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hoehn and Yahr Stage 0-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hoehn and Yahr Stage 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class of Symptomatic Therapy, MAOB Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Levodopa Equivalent Daily Dose</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1066.5" spread="519.7"/>
                    <measurement group_id="B2" value="971.8" spread="251.4"/>
                    <measurement group_id="B3" value="1012.5" spread="390.5"/>
                    <measurement group_id="B4" value="1016.9" spread="398.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education Adjusted MoCA Score</title>
          <description>Measure Description: Montreal Cognitive Assessment (MoCA) is one-page 30-point test to detect cognitive impairment. Baseline MoCA score ranges from 23 to 30. Higher scores indicate better cognition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="2.4"/>
                    <measurement group_id="B2" value="27.4" spread="1.9"/>
                    <measurement group_id="B3" value="27.0" spread="2.4"/>
                    <measurement group_id="B4" value="27.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DRS-2</title>
          <description>Measure Description: Mattis Dementia Rating Scale 2 (DRS-2) is a test to screen for dementia in Parkinson's disease. Five subscales provide additional information on specific abilities: Attention, Initiation/Perseveration, Construction, Conceptualization, and Memory. DRS-2 score range is 0-144. Higher scores indicate better cognition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138.1" spread="5.7"/>
                    <measurement group_id="B2" value="137.8" spread="7.8"/>
                    <measurement group_id="B3" value="137.7" spread="6.3"/>
                    <measurement group_id="B4" value="137.9" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BDI-II</title>
          <description>Measure Description: Baseline Beck Depression Inventory (BDI) score ranges from 0 to 23. Higher scores indicate greater symptom severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="4.9"/>
                    <measurement group_id="B2" value="7.3" spread="5.4"/>
                    <measurement group_id="B3" value="6.6" spread="4.3"/>
                    <measurement group_id="B4" value="6.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PDSS</title>
          <description>Measure Description: Parkinson Disease Sleep Scale self-rate and quantify the level of sleep disruption being experienced in order to target treatment appropriately. Scores range from 0 to 150. Higher scores indicate greater symptom severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106.6" spread="21.8"/>
                    <measurement group_id="B2" value="115.3" spread="11.6"/>
                    <measurement group_id="B3" value="103.2" spread="18.6"/>
                    <measurement group_id="B4" value="108.3" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified S/E ADL</title>
          <description>Measure Description: Schwab and England Activities of Daily Living scale. Baseline SE/ADL ranges from 40 to 100. Smaller value stands for more disability from PD.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Modified S/E ADL OFF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="16.5"/>
                    <measurement group_id="B2" value="77.3" spread="17.8"/>
                    <measurement group_id="B3" value="77.0" spread="14.9"/>
                    <measurement group_id="B4" value="75.8" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified S/E ADL ON</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.8" spread="8.7"/>
                    <measurement group_id="B2" value="92.2" spread="5.8"/>
                    <measurement group_id="B3" value="87.0" spread="17.9"/>
                    <measurement group_id="B4" value="88.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PDQ-39</title>
          <description>Measure Description: Parkinson's Disease Questionnaire-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the past month. Baseline PDQ 39 score ranges from 0 to 52. Lower score shows better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.0" spread="12.7"/>
                    <measurement group_id="B2" value="19.0" spread="9.4"/>
                    <measurement group_id="B3" value="18.4" spread="10.3"/>
                    <measurement group_id="B4" value="18.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D</title>
          <description>Measure Description: EQ-5D summary index is derived by applying a formula that essentially attaches values (weights) to each of the levels in the 5 dimensions. The total index range is from 0-1. The Health Score range is 0-100 point scale where the participant marks his or her health related quality that day. Higher scores show better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>EQ-5D Summary Index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.79" spread="0.14"/>
                    <measurement group_id="B2" value="0.83" spread="0.13"/>
                    <measurement group_id="B3" value="0.78" spread="0.15"/>
                    <measurement group_id="B4" value="0.80" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D Health Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="25.1"/>
                    <measurement group_id="B2" value="71.5" spread="23.3"/>
                    <measurement group_id="B3" value="76.0" spread="15.9"/>
                    <measurement group_id="B4" value="72.8" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of Nilotinib Over Placebo</title>
        <description>The count of study participants who completed the 6-month study treatment period while active on their original assigned dose</description>
        <time_frame>6 months</time_frame>
        <population>Intent-to-treat population, all randomized subjects per arm. The Count of participants below are the number of participants that met the criteria for analysis of tolerability.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo enclosed in capsules to maintain the blind was administered orally once per day over the course of 6 months</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 150 mg</title>
            <description>Patients were administered 1 capsule of 150 mg Nilotinib and 1 capsule of matching placebo each day over the course of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 300 mg</title>
            <description>Patients were administered 2 capsules of 150 mg Nilotinib each day over the course of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Nilotinib Over Placebo</title>
          <description>The count of study participants who completed the 6-month study treatment period while active on their original assigned dose</description>
          <population>Intent-to-treat population, all randomized subjects per arm. The Count of participants below are the number of participants that met the criteria for analysis of tolerability.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3626</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided Fisher’s Exact tested the proportion of participants who met tolerability between the Nilotinib 150 group to the Placebo group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3895</p_value>
            <method>Fisher Exact</method>
            <method_desc>One-sided Fisher’s Exact tested the proportion of participants who met tolerability between the Nilotinib 300 group to the Placebo group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety of Nilotinib</title>
        <description>The count of study participants who experienced any treatment-related SAE in each treatment group</description>
        <time_frame>We assessed adverse events that were collected from the first dose of study drug until 60 days after the participant's last dose.</time_frame>
        <population>Intent-to-treat population, all randomized subjects. The counts refer to the number of participants that experienced an SAE in each treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo enclosed in capsules to maintain the blind was administered orally once per day over the course of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 150</title>
            <description>Patients were administered 1 capsule of 150 mg Nilotinib and 1 capsule of matching placebo each day over the course of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 300</title>
            <description>Patients were administered 2 capsules of 150 mg Nilotinib each day over the course of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Nilotinib</title>
          <description>The count of study participants who experienced any treatment-related SAE in each treatment group</description>
          <population>Intent-to-treat population, all randomized subjects. The counts refer to the number of participants that experienced an SAE in each treatment arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : p1 = p2, where p represents the proportion of SAEs for each group. HA : p1 ≠ p2</non_inferiority_desc>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
            <method_desc>Fisher’s Exact test compared a proportion of participants who experienced any serious adverse event in the Nilotinib 150 group and the Placebo group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : λ1 = λ2, where λ represents the rate of SAEs for each group. HA : λ1 ≠ λ2</non_inferiority_desc>
            <p_value>0.5689</p_value>
            <method>Regression, Poisson</method>
            <method_desc>Rates of serious adverse event between the Nilotinib 150 group and the placebo were also compared using a Poisson regression model</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.4977</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0451</ci_lower_limit>
            <ci_upper_limit>5.489</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : p1 = p3, where p represents the proportion of SAEs for each group. HA : p1 ≠ p3</non_inferiority_desc>
            <p_value>0.61</p_value>
            <method>Fisher Exact</method>
            <method_desc>Fisher’s Exact test compared a proportion of participants who experienced any serious adverse event in the Nilotinib 300 group and the Placebo group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : λ1 = λ3, where λ represents the rate of SAEs for each group. HA : λ1 ≠ λ3</non_inferiority_desc>
            <p_value>0.5940</p_value>
            <method>Regression, Poisson</method>
            <method_desc>Rates of serious adverse event between the Nilotinib 300 group and the placebo were also compared using a Poisson regression model</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.5206</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0472</ci_lower_limit>
            <ci_upper_limit>5.7409</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MDS-UPDRS Part III</title>
        <description>The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III is a motor examination in both practically defined medications OFF state (12 hrs post dose) and ON state (based on the participant/site investigator defined best ON and/or approximately 1 hour post dose). Measure Description: The part III subscale score ranges from 0-165. The Larger the value stands for more disability from PD.</description>
        <time_frame>The MDS-UPDRS Part III ON state was collected at baseline, day 14, day 30, month 3, month 6, 30 and 60 days post treatment. The OFF state was collected at baseline, month 3, month 6, 30 and 60 days post treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo enclosed in capsules to maintain the blind was administered orally twice per day over the course of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Nilotinib 150</title>
            <description>Patients were administered 1 capsule of 150 mg Nilotinib and 1 capsule of matching placebo each day over the course of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Nilotinib 300</title>
            <description>Patients were administered 2 capsules of 150 mg Nilotinib each day over the course of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MDS-UPDRS Part III</title>
          <description>The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III is a motor examination in both practically defined medications OFF state (12 hrs post dose) and ON state (based on the participant/site investigator defined best ON and/or approximately 1 hour post dose). Measure Description: The part III subscale score ranges from 0-165. The Larger the value stands for more disability from PD.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MDS-UPDRS Part III (ON)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.80" spread="8.85"/>
                    <measurement group_id="O2" value="24.76" spread="11.62"/>
                    <measurement group_id="O3" value="25.15" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 MDS-UPDRS Part III (ON)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.13" spread="11.29"/>
                    <measurement group_id="O2" value="27.58" spread="13.53"/>
                    <measurement group_id="O3" value="29.33" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 MDS-UPDRS Part III (ON)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.36" spread="10.00"/>
                    <measurement group_id="O2" value="26.84" spread="13.08"/>
                    <measurement group_id="O3" value="29.73" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 MDS-UPDRS Part III (ON)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.83" spread="9.23"/>
                    <measurement group_id="O2" value="24.88" spread="13.70"/>
                    <measurement group_id="O3" value="25.76" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 MDS-UPDRS Part III (ON)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.63" spread="9.86"/>
                    <measurement group_id="O2" value="24.43" spread="11.50"/>
                    <measurement group_id="O3" value="25.61" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Post MDS-UPDRS Part III (ON)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.52" spread="8.82"/>
                    <measurement group_id="O2" value="25.13" spread="12.26"/>
                    <measurement group_id="O3" value="26.79" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Day Post MDS-UPDRS Part III (ON)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.88" spread="10.88"/>
                    <measurement group_id="O2" value="23.91" spread="12.93"/>
                    <measurement group_id="O3" value="26.42" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline MDS-UPDRS Part III (OFF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.36" spread="13.51"/>
                    <measurement group_id="O2" value="42.84" spread="12.53"/>
                    <measurement group_id="O3" value="43.50" spread="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 MDS-UPDRS Part III (OFF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.92" spread="14.46"/>
                    <measurement group_id="O2" value="39.92" spread="12.41"/>
                    <measurement group_id="O3" value="41.04" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 MDS-UPDRS Part III (OFF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.21" spread="14.91"/>
                    <measurement group_id="O2" value="41.91" spread="13.40"/>
                    <measurement group_id="O3" value="43.96" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Post MDS-UPDRS Part III (OFF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.92" spread="14.15"/>
                    <measurement group_id="O2" value="41.48" spread="12.19"/>
                    <measurement group_id="O3" value="45.26" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Day Post MDS-UPDRS Part III (OFF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.36" spread="14.20"/>
                    <measurement group_id="O2" value="40.27" spread="11.33"/>
                    <measurement group_id="O3" value="43.00" spread="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The key secondary objective is to conduct a futility analysis within each treatment group which examines the observed change in the MDS-UPDRS Part III ON within the two dose groups compared to previously reported changes from the Pagan et al (2016) study (NCT02281474).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The hypotheses of interest (H0: δ ≤ -9.8 (7 x 1.4) vs. HA: δ &gt; -9.8) where δ represents the change from baseline to 6 months using the MDS-UPDRS Part III ON in the Nilotinib 150 mg treatment group. The hypotheses of interest were evaluated based on an assessment of parameter estimates from a non-linear mixed effects model, adjusted for a participant’s Levodopa Equivalent Daily Dose (LEDD) at each time point.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The key secondary objective is to conduct a futility analysis within each treatment group which examines the observed change in the MDS-UPDRS Part III ON within the two dose groups compared to previously reported changes from the Pagan et al (2016) study (NCT02281474).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The hypotheses of interest (H0: δ ≤ -9.8 (7 x 1.4) vs. HA: δ &gt; -9.8) where δ represents the change from baseline to 6 months using the MDS-UPDRS Part III ON in the Nilotinib 300 mg treatment group. The hypotheses of interest were evaluated based on an assessment of parameter estimates from a non-linear mixed effects model, adjusted for a participant’s Levodopa Equivalent Daily Dose (LEDD) at each time point.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional secondary objective #1 is to establish the degree of symptomatic effect of Nilotinib as measured by the change in the MDS_UPDRS Part III ON score between baseline and 1 month.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : β1 = β 2 = β 3, where β represents the slope for each group. HA : at least one β i ≠ β j. Using the same LMM as in the key secondary analysis, a two degree of freedom test was used to test for any differences in the slopes from baseline to 1 month for the three treatment groups.</non_inferiority_desc>
            <p_value>0.031</p_value>
            <method>Mixed Models Analysis</method>
            <other_analysis_desc>In order to assess which group may be driving these findings, pairwise comparisons were also utilized (Nilotinib 150 vs PBO at 1 Month, Nilotinib 300 vs PBO at 1 month, Nilotinib 300 vs Nilotinib 150 at 1 month).</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional secondary objective #2 is to establish the degree of symptomatic effect of Nilotinib as measured by the change in the MDS_UPDRS Part III ON score between the final visit on study drug and 30 days off study drug.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : β1 = β 2 = β 3, where β represents the slope for each group. HA : at least one β i ≠ β j. For this analysis, a separate LMM was constructed, modeling the change from final visit on study drug to the 30 and 60 day follow up visits, while adjusting for the MDS-UPDRS Part III ON scores at the final visit on study drug as well as the Levodopa Equivalent Daily Dose (LEDD) at each visit.</non_inferiority_desc>
            <p_value>0.47</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional secondary objective #3 is to assess the impact of Nilotinib on the progression of PD disability as measured by the change in the MDS_UPDRS Part III ON score between baseline and 6 months.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : β1 = β 2 = β 3, where β represents the slope for each group. HA : at least one β i ≠ β j. Using the same LMM as in the key secondary analysis, a two degree of freedom test was used to test for any differences in the slopes from baseline to 6 months for the three treatment groups.</non_inferiority_desc>
            <p_value>0.077</p_value>
            <method>Mixed Models Analysis</method>
            <other_analysis_desc>Pairwise comparisons were also examined for trends (Active 150 vs PBO at 6 Months, Active 300 vs PBO at 6 months).</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional secondary objective #3 is to assess the impact of Nilotinib on the progression of PD disability as measured by the change in the MDS_UPDRS Part III OFF score between baseline and 6 months.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>H0 : β1 = β 2 = β 3, where β represents the slope for each group. HA : at least one β i ≠ β j. Using a similar LMM as in the key secondary analysis, except simplified to only include baseline, month 3 and month 6, a two degree of freedom test was used to test for any differences in the slopes from baseline to 6 months for the three treatment groups.</non_inferiority_desc>
            <p_value>0.17</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events were collected following the first dose of study drug until 30 days after the participant’s last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo enclosed in capsules to maintain the blind was administered orally once per day over the course of 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Nilotinib 150</title>
          <description>Patients were administered 1 capsule of 150 mg Nilotinib and 1 capsule of matching placebo once per day over the course of 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Nilotinib 300</title>
          <description>Patients were administered 2 capsules of 150 mg Nilotinib once per day over the course of 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Amylase Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>CSF protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tanya Simuni</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-2970</phone>
      <email>Tatyana.Simuni@nm.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

